. 2014 Jan;184(1):260–270. doi: 10.1016/j.ajpath.2013.09.023

Table 2.

Relative Chemical Sensitivities of FANC-Null Genotypes

Treatment	Class	Pharmacogenetic windows (IC₅₀ of null cells)^∗
Treatment	Class	PALB2^−/−	BRCA2^−/−	FANCC^−/−/−	FANCG^−/−
Melphalan	Cross-linker	20× (0.25 μmol/L)	25×^†	14×^†	14×^†
Mitomycin C	Cross-linker	17× (10 nmol/L)	23×^†	13×^†	12×^†
Cisplatin	Cross-linker	15× (0.6–0.7 μmol/L)	16×^†	9×^†	7×^†
KU0058948	PARP inhibitor	1000× (0.075 μmol/L)	1133× (0.022 μmol/L)	3×	3× (17 μmol/L)
Etoposide	Topoisomerase II inhibitor	8× (50–60 nmol/L)	10×^†	— ^†	— ^†
Camptothecin	Topoisomerase I inhibitor	6× (0.625 nmol/L)	6×^†	ND	ND
Formaldehyde	1-C aldehyde	—	—	2.8× (2 μmol/L)	2.8× (2 μmol/L)
Acetaldehyde	2-C aldehyde	22× (0.7 mmol/L)	19× (∼1 mmol/L)	—	2.4× (5.3 mmol/L)
Other tested aldehydes^‡	2-9C aldehydes	—	—	ND	ND

ND, not done; —, less than twofold window.

^∗

Windows were defined as the ratio of the IC₅₀ values of parental cells and gene-knockout cells; data are from the graphical results of Figure 4 and Supplemental Figure S2.

^†

Data from our prior reports.^8,29

^‡

See Results.